Stimulus Equivalence Learning in Acquired Brain Injury.

May 20, 2026 updated by: Klimmendaal Revalidatiespecialisten

The Principle of Stimulus Equivalence Learning and Its Neuropsychological Correlates in Adults With Acquired Brain Injury (ABI).

Stimulus Equivalence Learning (SEL) is a form of learning in which stimuli (such as words, pictures, or sounds) become linked to one another in memory, even though this specific connection has not been directly taught. In a typical SEL task, two relations are taught explicitly (A→B and A→C), and the untrained relation (B→C) is then tested. This indirect relation is not intentionally or consciously learned and is considered a form of implicit learning. The principle of stimulus equivalence learning is still rarely applied in cognitive rehabilitation after acquired brain injury (ABI), with the exception of a few small (N=1) treatment studies that have shown positive effects. However, it remains unclear to what extent ABI may affect the ability to acquire stimulus equivalence.

Study Overview

Status

Recruiting

Study Type

Observational

Enrollment (Estimated)

40

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Gelderland
      • Arnhem, Gelderland, Netherlands, 6813 GG
        • Recruiting
        • Klimmendaal Revalidatiespecialisten
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

ABI patients (>3 months post-injury), including stroke, traumatic brain injury, brain tumor, encephalitis, and out-of-hospital cardiac arrest (OHCA).

Description

Inclusion Criteria:

ABI patients (>3 months post-injury), including stroke, traumatic brain injury, brain tumor, encephalitis, and out-of-hospital cardiac arrest (OHCA).

Exclusion Criteria:

Neurodegenerative disorders Severe psychiatric disorders (including suicidality) Insufficient command of the Dutch language Severe cognitive impairments, aphasia, or visual or hearing problems that make test administration impossible

An additional exclusion criterion for controls was any medical condition that could lead to cognitive impairment beyond normal aging, including stroke, TBI, brain tumor, or other forms of brain injury.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
healthy controls
acquired brain injury

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Modified Rutgers Equivalence Learning Task (mRAET)
Time Frame: Day 1
The original RAET is an experimental paradigm in which faces have to be paired with colored fish. For the current study, this task has been adapted into a more ecologically valid version focused on medication intake, in which relationships are learned between the shape of a pill, the function of the pill, the time of intake, and the (fictional) brand name.
Day 1

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Location Learning Test (LLT)
Time Frame: Day 1
The LLT is a test that can be used to measure episodic spatial memory for object locations. Normalized scores for immediate and delayed spatial memory are computed (percentiles 0-100).
Day 1
Wechsler Adult Intelligence Scale IV-NL digit span (WAIS-IV-NL DS)
Time Frame: Day 1
The digit span is a measure of verbal working memory. Normalized standard scores can be computed (range 0-19, mean: 10, standard deviation: 3).
Day 1
Everyday memory questionnaire-revised (EMQ-R)
Time Frame: Day 1
This is a 13-item scale of the everyday memory functioning.
Day 1
Trial Making Test
Time Frame: Day 1
The Trail Making Test (TMT) is a neuropsychological test that measures processing speed, visual attention, and task switching.
Day 1
Stroop
Time Frame: Day 1
The Stroop Test is a cognitive task that measures selective attention, processing speed, and the ability to inhibit automatic responses. Participants are shown color words printed in incongruent ink colors (e.g., the word "red" printed in blue ink) and must name the ink color rather than read the word. The interference effect-slower or less accurate responses-reflects challenges in cognitive control and response inhibition.
Day 1
Rey Auditory Verbal Learning Test (RAVLT)
Time Frame: Day 1
The Rey Auditory Verbal Learning Test, RAVLT) is a verbal learning and memory task in which a list of 15 unrelated words is read aloud over several trials. The participant is asked to recall as many words as possible after each trial, and later again after a delay. The test assesses immediate recall, learning ability, retention, and recognition memory.
Day 1
Serial Reaction Time Task (SRTT)
Time Frame: Day 1

Participants respond to the location of a black circle that appears in one of four screen positions by pressing the corresponding response key as quickly and accurately as possible. After 12 practice trials, the task consists of 8 blocks of 60 trials.

Blocks 1-6 contain a fixed repeating sequence of locations (not disclosed to participants). Block 7 contains a different sequence, followed by a return to the original sequence in Block 8. After the task, participants complete questions assessing explicit awareness of the sequence.

Implicit learning is indicated by faster reaction times in Blocks 6 and 8 (repeated sequence) compared to Block 7 (irregular sequence).

Day 1

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 29, 2026

Primary Completion (Estimated)

June 1, 2026

Study Completion (Estimated)

July 1, 2026

Study Registration Dates

First Submitted

December 10, 2025

First Submitted That Met QC Criteria

January 8, 2026

First Posted (Actual)

January 15, 2026

Study Record Updates

Last Update Posted (Actual)

May 22, 2026

Last Update Submitted That Met QC Criteria

May 20, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acquired Brain Injury (Including Stroke)

Subscribe